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Abstract
This prespecified subanalysis of the global, randomized controlled phase III 
KEYNOTE-024 study of pembrolizumab vs chemotherapy in previously untreated 
metastatic non-small-cell lung cancer without EGFR/ALK alterations and a pro-
grammed death ligand 1 (PD-L1) tumor proportion score of 50% or higher evalu-
ated clinical outcomes among patients enrolled in Japan. Treatment consisted of 
pembrolizumab 200 mg every 3 weeks (35 cycles) or platinum-based chemotherapy 
(four to six cycles). The primary end-point was progression-free survival; second-
ary end-points included overall survival and safety. Of 305 patients randomized in 
KEYNOTE-024 overall, 40 patients were enrolled in Japan (all received treatment: 
pembrolizumab, n = 21; chemotherapy, n = 19). Median progression-free survival 
was 41.4 (95% confidence interval [CI], 4.2-42.5) months with pembrolizumab and 
4.1 (95% CI, 2.8-8.3) months with chemotherapy (hazard ratio [HR], 0.27 [95% CI, 
0.11-0.65]; one-sided, nominal P = .001). Median overall survival was not reached 
(NR) (95% CI, 22.9‒NR) and 21.5 (95% CI, 5.2-35.0) months, respectively (HR, 0.39 
[95% CI, 0.17-0.91]; one-sided, nominal P = .012). Treatment-related adverse events 
occurred in 21/21 (100%) pembrolizumab-treated and 18/19 (95%) chemotherapy-
treated patients; eight patients (38%) and nine patients (47%), respectively, had grade 
3-5 events. Immune-mediated adverse events and infusion reactions occurred in 
11 pembrolizumab-treated patients (52%) and four chemotherapy-treated patients 
(21%), respectively; four patients (19%) and one patient (5%), respectively, had grade 
3-5 events. Consistent with results from KEYNOTE-024 overall, first-line pembroli-
zumab improved progression-free survival and overall survival vs chemotherapy with 
manageable safety among Japanese patients with metastatic non-small-cell lung can-
cer without EGFR/ALK alterations and a PD-L1 tumor proportion score of 50% or 
higher. The trial is registered with Clinicaltrials.gov: NCT02142738.
K E Y W O R D S
Japan, non-small-cell lung carcinoma, PD-L1 protein, pembrolizumab, treatment outcome
1  | INTRODUC TION
Lung cancer is the leading cause of cancer-related deaths world-
wide1 and represents approximately 20% of all cancer-related deaths 
in Japan.2 Platinum-based chemotherapy has historically been the 
standard first-line treatment for patients with advanced-stage non-
small-cell lung cancer (NSCLC), particularly those without targeta-
ble EGFR and ALK alterations3-5; however, immunotherapy directed 
at the PD-1 checkpoint pathway has more recently provided pa-
tients with a therapeutic option that can improve clinical outcomes 
over standard chemotherapy regimens.6 The most recent updates 
to lung cancer clinical practice guidelines in Japan now recommend 
the anti-PD-1 immunotherapy pembrolizumab as first-line treat-
ment in patients with metastatic NSCLC without targetable gene 
alterations and a PD-L1 TPS of 50% or higher.7
Pembrolizumab is a humanized IgG4 mAb that blocks the in-
teraction between PD-1 and its ligands PD-L1 and PD-L2, thereby 
promoting cytotoxic T-cell-mediated antitumor responses.8 The 
phase I KEYNOTE-001 trial was the first study to show an associ-
ation between PD-L1 expression and response to pembrolizumab, 
showing a higher response rate among patients with advanced 
NSCLC and a PD-L1 TPS of 50% or higher.9 The global phase III 
KEYNOTE-024 study subsequently found that patients with previ-
ously untreated metastatic NSCLC without EGFR mutations or ALK 
translocations and a PD-L1 TPS of 50% or higher had significantly 
longer OS (HR, 0.60; 95% CI, 0.41-0.89; P = .005) and favorable 
safety outcomes with pembrolizumab vs platinum-based chemo-
therapy.10 A recent updated analysis from KEYNOTE-024 showed 
that pembrolizumab continued to prolong OS compared with 
chemotherapy with longer follow-up (HR for OS, 0.63; 95% CI, 
0.47-0.86; nominal P = .002), despite an increase in the number of 
patients who crossed over from chemotherapy to pembrolizumab 
(82 patients vs 66 patients who crossed over to pembrolizumab on 
study in the previous analysis).11
Previous analyses from registry data and clinical trials of anti-
cancer therapies for NSCLC suggest that Asian patients might have 
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better survival outcomes than non-Asian patients.12,13 Here, we re-
port results from patients enrolled in the KEYNOTE-024 study in 
Japan.10
2  | MATERIAL S AND METHODS
2.1 | Patients
Eligibility criteria for enrollment in the KEYNOTE-024 study have 
been previously published10; this subanalysis included patients en-
rolled in KEYNOTE-024 from 23 sites in Japan. In short, adult pa-
tients aged 18 years or older were eligible if they had previously 
untreated stage IV NSCLC without activating EGFR mutations or ALK 
translocations, a PD-L1 TPS of 50% or higher, measurable disease 
based on RECIST version 1.1, and an ECOG performance status of 
0 or 1. For evaluation of PD-L1 status, patients must have provided 
a tumor tissue sample obtained at the time of or after diagnosis of 
metastatic disease and before any adjuvant or neoadjuvant therapy. 
Patients were ineligible if they had untreated brain metastases, ac-
tive autoimmune disease that required systemic treatment, had re-
ceived systemic steroid therapy within 3 days before the first dose 
of study medication or were receiving any other immunosuppressive 
medication, or had interstitial lung disease or a history of pneumoni-
tis that required steroid treatment.
All patients provided written informed consent before enroll-
ment. The trial protocol and all amendments were approved by an 
institutional review board or independent ethics committee at each 
study site, and the trial was carried out in accordance with Good 
Clinical Practice guidelines and the Declaration of Helsinki.
2.2 | Study design
This was a prespecified subanalysis of the phase III, open-label, 
randomized KEYNOTE-024 study (ClinicalTrials.gov identifier, 
NCT02142738). As described previously,10 patients were ran-
domly assigned in a 1:1 ratio to receive either i.v. pembrolizumab 
200 mg every 3 weeks for up to 35 cycles or the investigator’s 
choice of one of the following five platinum-based chemotherapy 
regimens, selected before randomization, for four to six cycles: 
carboplatin or cisplatin plus pemetrexed, carboplatin or cisplatin 
plus gemcitabine, or carboplatin plus paclitaxel. Pemetrexed-
containing regimens were permitted only for patients with non-
squamous tumors, and pemetrexed maintenance therapy could 
continue after the combination chemotherapy regimen was 
completed. Randomization was stratified by ECOG performance 
status (0 vs 1) and tumor histology (squamous vs nonsquamous). 
Treatment continued for the prespecified number of cycles or until 
radiologic disease progression per RECIST version 1.1 by investi-
gator review, unacceptable toxicity, concurrent illness precluding 
further treatment, or a decision was made by the patient or the in-
vestigator to withdraw treatment. Crossover from chemotherapy 
to pembrolizumab was permitted for patients with documented 
disease progression (per RECIST version 1.1 by BICR) who met 
safety criteria. Patients in either treatment arm who were consid-
ered to be deriving clinical benefit and were clinically stable (ie no 
signs and symptoms of clinically significant disease progression, 
no rapid disease progression or progressive tumor requiring ur-
gent alternative treatment, and no decline in ECOG performance 
status) could continue to receive treatment after disease progres-
sion. Patients in the pembrolizumab arm who achieved a complete 
response could discontinue treatment if they had been treated for 
at least 6 months and had received at least two treatments beyond 
the initial date of complete response.10 Patients who stopped pem-
brolizumab after a complete response or after completing 2 years 
(35 cycles) of pembrolizumab and subsequently had disease pro-
gression could receive a second course of pembrolizumab for up 
to 17 cycles if they had received no other anticancer therapy since 
the last pembrolizumab dose and continued to meet the required 
eligibility criteria.
2.3 | End-points
The end-points in this preplanned subgroup analysis of patients en-
rolled in KEYNOTE-024 in Japan were the same as for the overall 
study. The primary end-point in the KEYNOTE-024 study was PFS, 
defined as the time from randomization to the first of either doc-
umented disease progression (per RECIST version 1.1 by BICR) or 
death from any cause. Secondary end-points were OS, defined as 
the time from randomization to death from any cause; ORR, defined 
as the proportion of patients with a confirmed complete or partial 
response (per RECIST version 1.1 by BICR); and safety. Duration of 
response was an exploratory end-point, and was defined as the time 
from the first documentation of a complete or partial response to 
disease progression.10
2.4 | Assessments
A central laboratory assessed PD-L1 expression in formalin-fixed 
tumor samples obtained through core-needle or excisional biopsy 
or from tissue resected at the time of or after diagnosis of meta-
static disease from a site not previously irradiated using the PD-L1 
IHC 22C3 pharmDx assay (Agilent Technologies).14 Computed to-
mography (preferred) or MRI was carried out every 9 weeks, with 
tumor response assessed per RECIST version 1.1 by BICR. After the 
end of treatment, patients were monitored for disease status every 
3 months until disease progression, initiation of new anticancer ther-
apy, withdrawal of consent, loss to follow-up, or death; once imaging 
assessments were stopped (ie for progressive disease or for starting 
a new anticancer therapy) survival follow-up was undertaken ap-
proximately every 2 months until death or withdrawal of consent. 
Safety was monitored throughout the study and for 30 days or more 
after treatment discontinuation (90 days for serious AEs and AEs 
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of interest). All AEs were graded in severity per the NCI’s Common 
Terminology Criteria for Adverse Events version 4.0.
2.5 | Statistical analysis
Statistical methods for this subanalysis of the KEYNOTE-024 study 
were the same as those of the primary analysis,10 except that only 
those patients enrolled in Japan were included. Efficacy analyses 
included all randomized patients, according to the treatment as-
signed (intention-to-treat population); safety analyses included 
all patients who received at least one dose of treatment, accord-
ing to the treatment received. Both PFS and OS were estimated 
using the Kaplan-Meier method. For the analysis of PFS, patients 
who were alive without disease progression and had not initiated 
new anticancer therapy or who were lost to follow-up were cen-
sored at the time of last tumor assessment. For the analysis of OS, 
patients without documented death were censored at the time of 
last follow-up. Between-group differences in PFS and OS were as-
sessed using a stratified log-rank test. Hazard ratios and associated 
95% CIs were assessed using a stratified Cox proportional hazards 
model with Efron’s method of handling ties. The stratified Miettinen 
and Nurminen method was used to assess treatment differences in 
ORR; patients with missing data were considered nonresponders. 
Stratification factors used for randomization were also applied to 
the analyses. One-sided nominal P values are provided for this sub-
analysis. The data cut-off date for this analysis was 15 February 2019.
3  | RESULTS
3.1 | Patients and treatment
Among 305 patients randomized in the overall KEYNOTE-024 study 
population (pembrolizumab, n = 154; chemotherapy, n = 151),10 
40 patients were randomized at Japanese sites (pembrolizumab, 
n = 21; chemotherapy, n = 19; Figure 1) between November 2014 
and October 2015, all of whom received treatment as assigned. In 
the chemotherapy arm, 10 patients crossed over to pembrolizumab 
on study (53%) and an additional three patients received anti-PD-1 
treatment outside of cross-over, for an effective cross-over rate of 
68% in the intention-to-treat population. Of patients initially allo-
cated to pembrolizumab, eight patients (38%) received subsequent 
platinum-based chemotherapy.
F I G U R E  1   CONSORT flow diagram of Japanese patients enrolled in KEYNOTE-024 to evaluate pembrolizumab vs chemotherapy in 
metastatic non-small-cell lung cancer. aThe remaining patients did not meet study eligibility criteria (n = 14). bIncludes 10 patients who 
crossed over to pembrolizumab treatment during the study. cIncludes clinical progression. PD-L1, programmed death ligand 1; TPS, tumor 
proportion score
17 Discontinued treatmentb
15 Progressive diseasec
2 Adverse event
2 Completed
40 Randomized 1:1
21 Allocated to pembrolizumab
21 Received assigned treatment
19 Allocated to chemotherapy
19 Received assigned treatment
7 Carboplatin plus pemetrexed 
(4 had pemetrexed maintenance)
10 Cisplatin plus pemetrexed
(2 had pemetrexed maintenance)
2 Carboplatin plus paclitaxel
186 Patients with samples for PD-L1 evaluation
202 Patients screened in Japan
54 Patients with PD-L1 TPS ≥50%
118 PD-L1 TPS <50%
172 Patients with PD-L1 assay 
resultsa
21 Intention-to-treat population
21 Safety population
19 Intention-to-treat population
19 Safety population
14 Discontinued treatment
    9 Progressive diseasec
5 Adverse event
7 Completed
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Patient demographic and baseline clinical characteristics were 
generally well balanced between the treatment arms (Table 1). Most 
patients had nonsquamous tumors (86% in the pembrolizumab arm 
and 95% in the chemotherapy arm) and were former or current 
smokers (95% and 100%, respectively). Median treatment expo-
sure as of the data cut-off date (15 February 2019) was 13.1 months 
(range, 0.03-47.6 months) in the pembrolizumab arm and 3.5 months 
(range, 0.03-11.8 months) in the chemotherapy arm, and median 
time from randomization to data cut-off was 43.3 months (range, 
40.7-50.5 months).
3.2 | Efficacy outcomes
A total of 27 PFS events occurred among the 40 patients enrolled in 
Japan, with few events occurring in the pembrolizumab arm (n = 10). 
The median PFS was 41.4 (95% CI, 4.2-42.5) with pembrolizumab and 
was 4.1 months (95% CI, 2.8-8.3) with chemotherapy (HR for PFS, 
0.27; 95% CI, 0.11-0.65; one-sided, nominal P = .001; Figure 2A). In 
addition, the estimated PFS rate at 1 year was higher in the pem-
brolizumab arm (64% [95% CI, 39%-81%]) vs the chemotherapy arm 
(25% [95% CI, 9%-46%]).
At the time of data cut-off, approximately half of the patients had 
died (pembrolizumab arm, n = 9; chemotherapy arm, n = 14). Overall 
survival was longer with pembrolizumab than with chemotherapy. 
Median OS was NR in the pembrolizumab arm (22.9-NR) and was 
21.5 months (95% CI, 5.2-35.0) in the chemotherapy arm (HR for OS, 
0.39; 95% CI, 0.17-0.91; one-sided, nominal P = .012; Figure 2B). The 
estimated OS rates in the pembrolizumab arm vs the chemotherapy 
arm were 86% (95% CI, 62%-95%) vs 63% (95% CI, 38%-80%) at 
1 year, 71% (95% CI, 47%-86%) vs 37% (95% CI, 17%-58%) at 2 years, 
and 67% (95% CI, 43%‒83%) vs 26% (95% CI, 10%-47%) at 3 years.
The ORR was 62% (95% CI, 38%-82%) in the pembrolizumab 
arm and 26% (95% CI, 9%-51%) in the chemotherapy arm (one-sided, 
nominal P = .019). The median duration of response was NR (range, 
6.2+ to 20.6+ months) in the pembrolizumab arm and 9.8 months 
(range, 4.8+ to 10.4 months) in the chemotherapy arm (plus signs in 
ranges indicate nondisease progression at the last assessment [cen-
sored] for the patient with the minimum/maximum response dura-
tion). Among patients in the pembrolizumab arm who had a complete 
(n = 1) or partial (n = 12) response, seven patients had completed 35 
cycles (2 years) of treatment at the time of data cut-off (Figure 3). 
Of these seven patients, three received a second course of pem-
brolizumab (one completed 17 cycles and two discontinued due to 
progressive disease; all three remained alive at data cut-off).
3.3 | Safety
Treatment-related AEs of any grade occurred in all 21 patients 
treated with pembrolizumab and 18 of the 19 patients (95%) treated 
with chemotherapy in this Japanese cohort (Table 2). The most com-
mon treatment-related AEs in the pembrolizumab arm were pyrexia 
(n = 5), diarrhea (n = 4), and rash (n = 4), and the most common 
in the chemotherapy arm were decreased appetite (n = 12), nausea 
(n = 11), and anemia (n = 9). Treatment-related AEs of grade 3-5 oc-
curred in eight patients (38%) in the pembrolizumab arm and nine 
patients (47%) in the chemotherapy arm. Four patients (19%) in the 
pembrolizumab arm and one patient (5%) in the chemotherapy arm 
discontinued treatment because of treatment-related AEs. No pa-
tient in the pembrolizumab arm and one patient (5%) in the chemo-
therapy arm died due to a treatment-related AE. Immune-mediated 
AEs and infusion reactions of any grade, and regardless of relation-
ship to treatment as assessed by the investigator, occurred in 11 pa-
tients (52%) in the pembrolizumab arm and in four patients (21%) in 
the chemotherapy arm (Table 2). The most common events in the 
pembrolizumab arm (occurring in at least 10% of patients) were in-
fusion reactions (n = 4; 19%), and pneumonitis and hypothyroidism 
(each n = 3; 14%). Grade 3-5 immune-mediated AEs occurred in four 
patients (19%) in the pembrolizumab arm (grade 3 hepatitis, severe 
skin reaction, and uveitis, and grade 4 pneumonitis, all in one pa-
tient each) and one patient (5%) in the chemotherapy arm (grade 3 
pneumonitis).
4  | DISCUSSION
This prespecified subanalysis of KEYNOTE-024 showed that pem-
brolizumab prolonged PFS over platinum-based chemotherapy 
TA B L E  1   Patient demographic and baseline clinical 
characteristics of Japanese patients enrolled in KEYNOTE-024
Characteristic
Pembrolizumab 
(n = 21)
Chemotherapy 
(n = 19)
n (%)a  n (%)a 
Age (y)
Median 66 67
Range 40-80 53-77
Male sex 16 (76) 18 (95)
ECOG performance status
0 7 (33) 8 (42)
1 14 (67) 11 (58)
Smoking status
Former/current 20 (95) 19 (100)
Never 1 (5) 0
Histology
Squamous 3 (14) 1 (5)
Nonsquamous 18 (86) 18 (95)
Brain metastases 1 (5) 1 (5)
Prior neoadjuvant 
therapy
0 0
Prior adjuvant therapy 0 0
aData are n (%), unless otherwise noted. 
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F I G U R E  2   Kaplan-Meier estimates of (A) progression-free survival per RECIST version 1.1 per independent central review and (B) overall 
survival in patients with metastatic non-small-cell lung cancer treated with pembrolizumab or chemotherapy. CI, confidence interval; HR, 
hazard ratio; NR, not reached; RECIST, response evaluation criteria in solid tumors
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(HR for disease progression or death, 0.27; one-sided, nominal 
P = .001) among patients enrolled in Japan with previously untreated 
metastatic NSCLC without targetable EGFR/ALK alterations and a 
PD-L1 TPS of 50% or more. Of note, few PFS events had occurred in 
either treatment arm after a median study follow-up of 43.3 months. 
In addition, pembrolizumab prolonged OS over chemotherapy (HR for 
death, 0.39; one-sided, nominal P = .012). With few OS events occur-
ring in the pembrolizumab arm, median OS was not reached. Treatment 
with pembrolizumab was associated with a higher ORR compared with 
chemotherapy (62% vs 26%). In addition, pembrolizumab had a man-
ageable safety profile, and no new safety signals were identified in 
this subset of Japanese patients relative to previous studies evaluating 
pembrolizumab monotherapy in patients with advanced NSCLC.9,10,15
The favorable efficacy observed with pembrolizumab in this 
subanalysis among patients in KEYNOTE-024 enrolled in Japan is 
consistent with the significantly longer PFS (HR, 0.50; P < .001) 
and OS (HR, 0.60; P = .005) observed with pembrolizumab vs che-
motherapy in the overall study population,9,10,15 with somewhat 
lower HRs for PFS (0.27) and OS (0.39) in the current analysis. 
Although the reason for these lower HRs is uncertain, several fac-
tors might have contributed, including potential differences in base-
line characteristics, patient care practices in Japan, or in treatment 
responses between Japanese and non-Asian populations.13,16 The 
smaller number of patients in this subgroup analysis and few PFS 
and OS events in either treatment arm might have also contributed. 
Notably, the positive results from the current analysis are consis-
tent with the positive findings in the large, multicenter, randomized 
controlled phase III KEYNOTE-042 study as well.17 Similar to results 
from the overall KEYNOTE-024 study noted above, KEYNOTE-042 
showed an OS benefit with pembrolizumab vs platinum-based 
chemotherapy in patients with previously untreated locally ad-
vanced or metastatic NSCLC without EGFR or ALK alterations and a 
PD-L1 TPS of 50% or higher (HR, 0.69; P = .0003), and additionally 
showed OS benefit in the overall population with PD-L1 TPS of at 
least 1% (HR, 0.81; P = .0018).17 Together, these findings provide 
support for the use of pembrolizumab monotherapy as first-line 
treatment for PD-L1-positive (TPS ≥ 1%) advanced NSCLC, which 
has received regulatory approval in Japan.18 Significant OS bene-
fit has also been shown with pembrolizumab plus platinum-based 
chemotherapy vs chemotherapy alone in patients with previously 
untreated metastatic NSCLC without EGFR or ALK alterations, ir-
respective of PD-L1 expression, in the phase III placebo-controlled 
studies KEYNOTE-189 (nonsquamous; HR, 0.49; P < .001) and 
KEYNOTE-407 (squamous; HR, 0.64; P < .001).19,20
F I G U R E  3   Duration of treatment and time to response among patients in the pembrolizumab arm of KEYNOTE-024 with a complete 
response (CR) or partial response (PR) per RECIST version 1.1 by independent central review. Bar lengths indicate duration of treatment 
(first-course, dark green; second-course, medium green) and months of follow-up (light green). Tumor response (ie, CR, PR, SD, PD) is 
expressed per RECIST version 1.1 by independent central review only. AE, adverse event; PD, progressive disease; PD-L1, programmed 
death ligand 1; SD, stable disease; TPS, tumor proportion score
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Importantly, the OS benefits with pembrolizumab monotherapy 
over chemotherapy among patients in this subanalysis and in the 
global KEYNOTE-024 study were observed despite relatively high 
cross-over rates (53% in the current analysis and 44% in the primary 
analysis of the global study).10 Moreover, the effective cross-over 
rate of 68% in the current analysis (after accounting for patients in 
the chemotherapy arm who received anti-PD-1/PD-L1 therapy out-
side of on-study cross-over) was similar to the effective cross-over 
rate in the most recent updated analysis from the KEYNOTE-024 
global study (65%), which continued to show an OS benefit with 
pembrolizumab (HR, 0.63; P = .002), further supporting the efficacy 
gains with pembrolizumab.11
TA B L E  2   Summary of adverse events (AEs) among patients from Japan in the as-treated population of KEYNOTE-024a
Treatment-related AEs b   
Pembrolizumab (n = 21) Chemotherapy (n = 19)
n (%) n (%)
Any grade 21 (100) 18 (95)
Grade 3-5 8 (38) 9 (47)
Led to discontinuation c   4 (19) 1 (5)
Led to death 0 1 (5)
Treatment-related AEsb  occurring in ≥15% of 
patients in either arm
Any grade Grade 3-5 Any grade Grade 3-5
n (%) n (%) n (%) n (%)
Pyrexia 5 (24) 0 (0) 2 (11) 0 (0)
Diarrhea 4 (19) 1 (5) 3 (16) 0 (0)
Rash 4 (19) 0 (0) 0 (0) 0 (0)
Decreased appetite 3 (14) 0 (0) 12 (63) 2 (11)
Anemia 2 (10) 1 (5) 9 (47) 5 (26)
Malaise 2 (10) 0 (0) 8 (42) 0 (0)
Hypoalbuminemia 2 (10) 2 (10) 4 (21) 2 (11)
Hiccups 1 (5) 0 (0) 6 (32) 0 (0)
Constipation 1 (5) 0 (0) 5 (26) 0 (0)
Peripheral sensory neuropathy 1 (5) 0 (0) 3 (16) 0 (0)
Nausea 0 (0) 0 (0) 11 (58) 0 (0)
Platelet count decreased 0 (0) 0 (0) 8 (42) 3 (16)
White blood cell count decreased 0 (0) 0 (0) 8 (42) 1 (5)
Neutrophil count decreased 0 (0) 0 (0) 4 (21) 1 (5)
Immune-mediated AEs and infusion reactionsd  n (%) n (%) n (%) n (%)
Any 11 (52) 4 (19) 4 (21) 1 (5)
Infusion reactions 4 (19) 0 (0) 1 (5) 0 (0)
Pneumonitis 3 (14) 1 (5) 1 (5) 1 (5)
Hypothyroidism 3 (14) 0 (0) 2 (11) 0 (0)
Colitis 1 (5) 0 (0) 0 (0) 0 (0)
Hepatitis 1 (5) 1 (5) 0 (0) 0 (0)
Hyperthyroidism 1 (5) 0 (0) 0 (0) 0 (0)
Severe skin reactions 1 (5) 1 (5) 0 (0) 0 (0)
Thyroiditis 1 (5) 0 (0) 0 (0) 0 (0)
Uveitis 1 (5) 1 (5) 0 (0) 0 (0)
Adrenal insufficiency 0 (0) 0 (0) 1 (5) 0 (0)
aThe as-treated population comprised all randomized patients who received at least one dose of study treatment, according to the treatment 
received. 
bAdverse events that were attributed to treatment by the investigator are listed. 
cTreatment-related AEs that led to discontinuation were: pneumonitis (n = 2), fatigue (n = 1), and uveitis (n = 1) among four patients in the 
pembrolizumab group, and hypoxia (n = 1) and pulmonary alveolar hemorrhage (resulting in death) in one patient in the chemotherapy group. 
dImmune-mediated AEs and infusion reactions are listed irrespective of attribution to study treatment by the investigator. 
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With a median treatment exposure of 13.1 months (range, 0.03-
47.6 months) in this subanalysis compared with 7 months (range, 0.03-
18.7 months) in the primary analysis of the KEYNOTE-024 study,10 
there were no additional safety concerns identified, supporting the 
tolerability of pembrolizumab in Japanese patients with metastatic 
NSCLC. In addition, the immune-mediated AEs and infusion reactions 
that occurred with pembrolizumab among the patients included in this 
subanalysis were consistent with those observed in previous clinical tri-
als evaluating pembrolizumab monotherapy in advanced NSCLC,9,10,15 
with few events of grade 3 or higher—a finding that is of particular clin-
ical relevance, as monitoring for these events is necessary in practice.
Key limitations of this subanalysis are that no alpha was allo-
cated, and because the data represent a subset of patients from the 
global KEYNOTE-024 study, the sample size was smaller (40 pa-
tients of 305 who were randomized in the global study). Accordingly, 
with fewer patients, fewer events of PFS and OS occurred, as noted 
above. However, despite the limited power of this analysis, the HRs 
for these end-points suggested substantial PFS and OS benefits 
with pembrolizumab over chemotherapy. Importantly, these results 
provide support for the efficacy and safety of pembrolizumab in 
Japanese patients with advanced NSCLC.
In conclusion, this subanalysis among patients enrolled in 
KEYNOTE-024 in Japan demonstrated the efficacy and safety ben-
efits of pembrolizumab vs platinum-based chemotherapy, as also 
observed in the primary analysis. These findings provide further 
support for the use of pembrolizumab monotherapy as first-line 
treatment in patients from Japan with metastatic NSCLC without 
activating EGFR mutations or ALK translocations and a PD-L1 TPS 
of 50% or higher.
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